Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study With a Long-Term, Open-Label Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients With Hemophilic Arthropathy
Conditions
Interventions
TRM-201 (Rofecoxib)
Placebo
Locations
46
United States
Orthopedic Hospital DBA Orthopedic Hemophilia Treatment Center
Los Angeles, California, United States
Center for Inherited Blood Disorders
Orange, California, United States
UC Davis Children's Hospital
Sacramento, California, United States
University of Colorado Hemophilia & Thrombosis Center
Aurora, Colorado, United States
Georgetown University Hospital - Medstar
Washington D.C., District of Columbia, United States
University of Florida - Shands
Gainesville, Florida, United States
Start Date
June 2, 2021
Primary Completion Date
September 28, 2022
Completion Date
September 28, 2022
Last Updated
October 27, 2022
Lead Sponsor
Tremeau Pharmceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions